MONTRÉAL, QUÉBEC--(Marketwired - Feb. 20, 2014) - Ms. Sarita Benchimol, the President and Chief Executive Officer of MédiMabs Inc., is pleased to announce the election to the MédiMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRS(C), FRCP(C), MACP, Dr. Claudio Cuello OC, MD, DSc, FRS(C), Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
Dr. Chase also accepted his appointment to the position of Chairman of the Board. His previous experience in the life science and biotech sector includes various senior executive and CEO positions in several world class biotech companies such as Glaxo Canada (GlaxoSmithKline), Connaught Vaccine (Pasteur Merieux Connaught), ImmunoVaccine Inc. and Shire Biologics Inc. He was also a member of the board of directors for public companies such as Conjuchem Inc., Acambis PLC, QLT Inc., and was most recently involved in the sale of Medicago Inc. to Mitsubishi Tanabe Pharma Corporation, as its Chairman of the Board.
"Dr. Chase and Mr. Wong are very welcome additions to our board of directors" commented Dr Claudio Cuello, one of the four founding shareholders of MédiMabs. "Dr. Chase brings to our unique antibody development company his broad life science business experience in both private and public entities and a unique skill set and knowledge in the areas of vaccine and immunology."
Mr. Wong is an experienced investment banker with vast experience in the capital markets, and brings to MédiMabs his financial and business expertise. As a CPA / chartered accountant, he is a co-founder and managing partner of Milton Capital Partners, an investment banking firm. He has been involved in several complex financing transactions, IPO transactions and debt restructuring on behalf of both creditors and debtors. He played instrumental roles in restructuring billions in distressed and defaulted debt, in Europe and North America. As a banker, he was responsible for relationship management of several multi-national public companies, and was involved in the debt and equity issues of several Fortune 500 corporations.
About MédiMabs Inc.
MédiMabs is a Canadian private company that specializes in the development of custom antibodies, the acquisition of licenses and the commercialization of research grade antibodies as well as related services to biomedical researchers, biotechnology and pharmaceutical companies worldwide. MédiMabs also has R&D programs to generate novel research, therapeutic and diagnostic antibodies. The Company was incorporated in 2006, and operates from its 12,000 square-foot research and production premises centrally located in Montréal, Québec. MédiMabs is the only company in Quebec providing some of these products and services, and the only Canadian antibody company providing top scientific personal support to its worldwide clients. MédiMabs' technica staff is further supported by a scientific advisory committee composed of world class scientists and researchers who are leaders in the areas of immunology, neurosciences and other medical research fields. Through its "Boutique Approach" for the delivery of services it responds to the critical need of both technical, and before and after sales support in monoclonal and polyclonal antibodies for the life sciences research.